Analysis of 130 Cases of Sympathetic Ophthalmia – A Retrospective Multicenter Case Series. (17th November 2019)

• Record Type: Journal Article
• Authors: Tan, Xiu Ling; Seen, Sophia; Dutta Majumder, Parthopratim; Ganesh, Sudha K.; Agarwal, Mamta; Soni, Aniruddh; Biswas, Jyotirmay; Aggarwal, Kanika; Mahendradas, Padmamalini; Gupta, Vishali; Ling, Ho Su; Teoh, Stephen; Pavesio, Carlos; Agrawal, Rupesh
• Is Part Of: Ocular immunology and inflammation. Volume 27:Number 8(2019)
• Page Start: 1259
• Page End: 1266
• Publication Date: 2019-11-17
• Subjects: Corticosteroids -- enucleation -- immunosuppressive therapy -- phthisis bulbi -- sympathetic ophthalmia -- trauma; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.1080/09273948.2018.1517894
• Languages: English
• ISSNs: 0927-3948

Abstract

ABSTRACT: Objective: To analyze the demographic profile, treatment, and visual outcome of the patients with sympathetic ophthalmia (SO) in a multicenter collaborative retrospective cohort study. Methods: Medical records of the patients with SO from UK, Singapore, India were reviewed for history of ocular trauma or surgery and subsequent development of uveitis consistent with SO, presenting symptoms, treatment, and visual outcomes. Results: A total of 130 patients were diagnosed with SO during the study period. Eighty-one (62.3%) patients were men. The mean age was 48.4 ± 15.5 years. The most common presenting symptom was blurring of vision (89.2%), followed by pain (29.2%) and floaters (23.8%). Ninety-two (70.7%) required additional immunosuppressive therapy. Thirty-six (27.9%) patients underwent enucleation of the inciting eye. Conclusions: SO is a potentially sight-threatening disease with high rates of visual loss. It warrants prompt evaluation and treatment. With the advances and availability in immunotherapy, the visual prognosis is relatively good.